$LH

Wilkinson Peter J sold $439K of LH

Wilkinson Peter J (SVP, Chief Accounting Officer) sold 1,420 shares of LABCORP HOLDINGS INC. (LH) at an average of $309.23 ($309.22–$309.23, $0.44M total) across 2 trades on 2026-08-03.

Original reporting
SEC EDGAR · Wilkinson Peter J
Published Aug 5, 2026, 3:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 3:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
low confidence
Mentioned
$LH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

The only new information is the specific open-market sale size, price range, and post-transaction holdings; it does not change LH’s operating outlook.

02

Market read

Traders may note insider selling, but there is no fundamental catalyst or guidance change tied to the filing.

03

What to watch

Insider sales are common and often not predictive; the disclosure lacks context on total holdings, compensation timing, or whether other insiders are buying.

Relevance 4/10Novelty 2/10Timing: filed 2026-08-05 after-hours/late session window (per timestamp)

Background

The article is an SEC Form 4 insider transaction report for Labcorp Holdings (LH) by Peter J. Wilkinson, SVP and Chief Accounting Officer.

Company-level read

Ticker impact

$LHNeutralLow confidence
Context

SEC Form 4 shows LH CFO Wilkinson sold 1,420 shares in open-market trades at about $309.23 on 2026-08-03.

Expected impact

Low likelihood of a sustained price move solely from this Form 4.

Evidence & confidence

The filing is an open-market sale, not a buy, and it does not include new company guidance, contracts, or regulatory actions.

Market effects

None.

None.

None.

Counterpoint

The sale may be driven by diversification or tax planning rather than a bearish view, especially without a 10b5-1 plan.

Key entities

  • LABCORP HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Wilkinson Peter J

    SVP, Chief Accounting Officer who sold shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

$LHMedAI 8/10

Labcorp to offer FDA-cleared Elecsys pTau-217 Alzheimer's test

Labcorp (LH) will offer the FDA-cleared Elecsys pTau-217 blood test, developed by Roche Diagnostics, to detect Alzheimer's-related amyloid pathology in individuals aged 55+ with cognitive decline. This is the first FDA-cleared single-biomarker test for both ruling in and out amyloid pathology, setting it apart from other options.

$LHMed

Why is Labcorp stock sliding today?

Labcorp (LH) stock fell 4.3% to $307.43 after its 2026 Investor Day, where it reaffirmed revenue guidance of $14.71B-$14.83B and EPS growth of 8.5%-11.5%. The market expected a guidance raise, and the lack of upside led to profit-taking. Broader market declines also pressured the stock.